metformin has been researched along with Endotoxemia in 8 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Endotoxemia: A condition characterized by the presence of ENDOTOXINS in the blood. On lysis, the outer cell wall of gram-negative bacteria enters the systemic circulation and initiates a pathophysiologic cascade of pro-inflammatory mediators.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin administration attenuates endotoxemia and enhances insulin signaling in high-fat fed mice, which contributes to its anti-diabetic effects." | 7.83 | Metformin exerts glucose-lowering action in high-fat fed mice via attenuating endotoxemia and enhancing insulin signaling. ( Chai, DD; Ren, LW; Yang, HY; Yu, ZW; Zhan, P; Zhou, ZY, 2016) |
| "Treatment with metformin reversed LPS-induced decline of AMPK phosphorylation." | 5.48 | Metformin alleviated endotoxemia-induced acute lung injury via restoring AMPK-dependent suppression of mTOR. ( Dai, J; Huang, J; Jiang, R; Tian, R; Wu, K; Yang, Y; Zhang, L, 2018) |
| "Metformin administration attenuates endotoxemia and enhances insulin signaling in high-fat fed mice, which contributes to its anti-diabetic effects." | 3.83 | Metformin exerts glucose-lowering action in high-fat fed mice via attenuating endotoxemia and enhancing insulin signaling. ( Chai, DD; Ren, LW; Yang, HY; Yu, ZW; Zhan, P; Zhou, ZY, 2016) |
| "Treatment with metformin reversed LPS-induced decline of AMPK phosphorylation." | 1.48 | Metformin alleviated endotoxemia-induced acute lung injury via restoring AMPK-dependent suppression of mTOR. ( Dai, J; Huang, J; Jiang, R; Tian, R; Wu, K; Yang, Y; Zhang, L, 2018) |
| "Rolipram was the most potent inhibitor of cytokine production (IC50 0." | 1.42 | Anti-inflammatory effects of four potential anti-endotoxaemic drugs assessed in vitro using equine whole blood assays. ( Bailey, SR; Bauquier, JR; Tudor, E, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, Y | 2 |
| Dong, R | 1 |
| Hu, D | 1 |
| Chen, Z | 1 |
| Fu, M | 1 |
| Wang, DW | 1 |
| Xu, X | 1 |
| Tu, L | 1 |
| Wu, K | 1 |
| Tian, R | 2 |
| Huang, J | 1 |
| Dai, J | 1 |
| Jiang, R | 1 |
| Zhang, L | 1 |
| Li, R | 1 |
| Liu, Y | 1 |
| Liu, J | 1 |
| Pan, T | 1 |
| Zhang, R | 1 |
| Liu, B | 1 |
| Chen, E | 1 |
| Tang, Y | 1 |
| Qu, H | 1 |
| Kim, J | 1 |
| Kwak, HJ | 1 |
| Cha, JY | 1 |
| Jeong, YS | 1 |
| Rhee, SD | 1 |
| Kim, KR | 1 |
| Cheon, HG | 1 |
| Bauquier, JR | 1 |
| Tudor, E | 1 |
| Bailey, SR | 1 |
| Zhou, ZY | 1 |
| Ren, LW | 1 |
| Zhan, P | 1 |
| Yang, HY | 1 |
| Chai, DD | 1 |
| Yu, ZW | 1 |
| Pedersen, C | 1 |
| Gallagher, E | 1 |
| Horton, F | 1 |
| Ellis, RJ | 1 |
| Ijaz, UZ | 1 |
| Wu, H | 1 |
| Jaiyeola, E | 1 |
| Diribe, O | 1 |
| Duparc, T | 1 |
| Cani, PD | 1 |
| Gibson, GR | 1 |
| Hinton, P | 1 |
| Wright, J | 1 |
| La Ragione, R | 1 |
| Robertson, MD | 1 |
| Tsoyi, K | 1 |
| Jang, HJ | 1 |
| Nizamutdinova, IT | 1 |
| Kim, YM | 1 |
| Lee, YS | 1 |
| Kim, HJ | 1 |
| Seo, HG | 1 |
| Lee, JH | 1 |
| Chang, KC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Improving Microcirculation and Microvascular Leakage in Sepsis Patients: A Comprehensive Clinical Study of Shenfu Injection[NCT06157320] | 40 participants (Anticipated) | Interventional | 2023-12-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for metformin and Endotoxemia
| Article | Year |
|---|---|
Host-microbiome interactions in human type 2 diabetes following prebiotic fibre (galacto-oligosaccharide) intake.
Topics: Adult; Aged; Biomarkers; Cohort Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Dysbiosis; | 2016 |
7 other studies available for metformin and Endotoxemia
| Article | Year |
|---|---|
Liver Kinase B1/AMP-Activated Protein Kinase Pathway Activation Attenuated the Progression of Endotoxemia in the Diabetic Mice.
Topics: AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Experimental; Disease Progression; Endoto | 2017 |
Metformin alleviated endotoxemia-induced acute lung injury via restoring AMPK-dependent suppression of mTOR.
Topics: Acute Lung Injury; AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Cytokines; Endo | 2018 |
Metformin ameliorates endotoxemia-induced endothelial pro-inflammatory responses via AMPK-dependent mediation of HDAC5 and KLF2.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Benzamides; Cell Adhesion; Cocul | 2019 |
Metformin suppresses lipopolysaccharide (LPS)-induced inflammatory response in murine macrophages via activating transcription factor-3 (ATF-3) induction.
Topics: Activating Transcription Factor 3; AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; | 2014 |
Anti-inflammatory effects of four potential anti-endotoxaemic drugs assessed in vitro using equine whole blood assays.
Topics: Animals; Anti-Inflammatory Agents; Azithromycin; Endotoxemia; Horse Diseases; Horses; In Vitro Techn | 2015 |
Metformin exerts glucose-lowering action in high-fat fed mice via attenuating endotoxemia and enhancing insulin signaling.
Topics: Animals; Anti-Bacterial Agents; Blood Glucose; Cells, Cultured; Diet, High-Fat; Endotoxemia; Humans; | 2016 |
Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice.
Topics: AMP-Activated Protein Kinases; Animals; Cells, Cultured; Cytokines; Endotoxemia; HMGB1 Protein; Inte | 2011 |